Immunologic nonresponsiveness to tumors

Critical Reviews in Oncogenesis

Volumn 9, Issue 1, 1998, Pages 35-41

  Antonia, Scott J ^a   Extermann, Martine ^a   Flavell, Richard A ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune tolerance; Tumor immunity

Indexed keywords

FAS LIGAND; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; CANCER IMMUNOTHERAPY; CLONAL ANERGY; CYTOKINE RELEASE; IMMUNOLOGICAL TOLERANCE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0031721706     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v9.i1.30     Document Type: Review

References (62)

1. Abbas, A. K., K. M. Murphy, and A. Sher: Functional diversity of helper T lymphocytes. Nature, 383:787-793 (1996).
2. Abdel-Wahab, Z., C. Weltz, D. Hester, N. Pickett, C. Vervaert, J. R. Barber, D. Jolly, and H. F. Seigler: A phase I clinical trial of immunotherapy with interferon-γ genemodified autologous melanoma cells: monitoring the humoral immune response. Cancer, 80:401-4-12 (1997).
3. Akbar, A. N., N. J. Borthwick, R. G. Wickremasinghe, P. Panayoitidis, D. Pilling, M. Bofill, S. Krajewski, J. C. Reed, and M. Salmon: Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T-cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol., 26:294-299 (1996).
4. Backer, J. C., T. Brabletz, C. Czerny, C. Termeer, and E. B. Brocker: Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T-cell clone by the autologons MHC class II+ melanoma. Int. Immunol., 5:1501-1508 (1993).
5. Boon, T. and P. van der Bruggen: Human tumor antigens recognized by T lymphocytes. J. Exp. Med, 183:725-729 (1996).
6. Bukowski, R. M: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 80:1198-1220. (1997)
7. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley: Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71:1093-1102 (1992).
8. Chen, L.: Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today, 19:27-30(1998).
9. Cresswell, P., M. J. Androlewicz, and B. Ortmann: Assembly and transport of class I MHC-peptide complexes. Ciba Found. Symp., 187:150-162 (1994).
10. Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer, and J. M. Walboomers: Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179:335-340 (1994).
11. Cua, D. J., D. R. Hinton, and S. A. Stohlman: Self-antigen-induced Th2 responses in experimental alleric encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J. Immunol., 155:4052-4059 (1995).
12. Dhein, J., H. Walczak, C. Baumler, K. Debatin, and P. H. Krammer: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373:438-441 (1995).
13. Disis, M. L. and M. A. Cheever: Oncogenic proteins as tumor antigens. Curr. Opin. Immunol., 8:637-642 (1996).
14. D'Adamio, L., K. M. Awad, and E. L. Reinherz: Thymic and peripheral apoptosis of antigen-specific T cells might cooperate in establishing self tolerance. Eur. J. Immunol., 23:747-753 (1993).
15. Falcone, M. and B. R. Bloom: A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J. Exp. Med., 185:901-907 (1997).
16. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol., 156:1095-1100 (1996).
17. Fearon, E. R. and B. Vogelstein: A genetic model for colorectal tumorigenesis. Cell, 61:759-767 (1990).
18. Fossum, B., A. C. Olsen, E. Thorsby, and G. Gaudernack: CD8+ T cells from a patient with colon carcinoma specific for a mutant p21 -ras-derived peptide are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother., 40:165-172 (1995).
19. Fujii, H., M. Inobe, F. Kimura, J. Murata, M. Murakami, Y. Onishi, I. Azuma, T. Uede, and I. Saiki: Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int. J. Cancer, 66:219-224 (1996).
20. Gaczynska, M., K. L. Rock, and A. L. Goldberg: Role of proteasomes in antigen presentation. Enzyme Protein, 47:354-369 (1993).
21. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon: Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol., 156:2909-2917 (1996).
22. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J. J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, and P. L. Stern: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today, 18:89-95 (1997).
23. Ghosh, P., K. L. Komschlies, M. Cippitelli, D. L. Longo, J. Subleski, J. Ye, A. Sica, H. A. Young, R. H. Wiltrout, and A. C. Ochoa: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst., 87:1478-1483 (1995).
24. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. U.S.A., 90:6586-6590 (1993).
25. Gombert, W., N. J. Borthwick, D. L. Wallace, H. Hyde, M. Bofill, D. Pilling, P. C. Beverley, G. Janossy, M. Salmon, and A. N. Akbar: Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expression. Immunology, 89: 397-404(1996).
26. Grewal, I. S., J. Xu, and R. A. Flavell: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature, 378:617-620 (1995).
27. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84:3261-3282 (1994).
28. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp: Melanoma cell expression of Fas (AP01/CD95) ligand: implications for tumor immune escape. Science, 274: 1363-1366 (1996).
29. Hartwell, L.: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71:543-546(1992).
30. Heinzel, F. P., M. D. Sadick, S. S. Mutha, and R. M. Locksley: Production of interferon-γ, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. U.S.A., 88:7011-7015 (1991).
31. Hoover H. C., Jr., J. S. Brandhorst, L. C. Peters, M. G. Surdyke, Y. Takeshita, J. Madariaga, L. R. Muenz, and M. G. Hanna, Jr.: Adjuvant active specific immuno-therapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol., 11:390-399 (1993).
32. Jachimczak, P., U. Bogdahn, J. Schneider, C. Behl, J. Meixensberger, R. Apfel, R. Domes, K. H. Schlingensiepen, and W. Brysch: The effect of transforming growth factor β2-specific phosphorothioate-antisense oligodeoxy-nucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg., 78:944-951 (1993).
33. Ju, S., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature, 373:444-448 (1995).
34. Kabelitz, D., T. Pohl, and K. Pechhold: Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol. Today, 14:338-339 (1993).
35. Lengauer, C., K. W. Kinzler, and B. Vogelstein: Genetic instability in colorectal cancers. Nature, 386:623-627 (1997).
36. Liblau, R. S., R. Tisch, S. Y. Shokat, X. Yang, N. Dumont, C. C. Goodnow, and H. O. McDevitt: Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc. Natl. Acad. Sci. U.S.A., 93: 3031-3036 (1996).
37. Loeb, L.: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res., 51:3075-3079 (1991).
38. Maeda, H. and A. Shiraishi: TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol., 156:73-78 (1996).
39. Martin, D. R. and R. G. Miller: In vivo administration of histoincompatable lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J. Exp. Med., 70:679-690 (1989).
40. Miller, J. F. and A. Basten: Mechanisms of tolerance to self. Curr. Opin. Immunol., 8:815-821 (1996).
41. Mueller, D. L., M. K. Jenkins, and R. H. Schwartz: Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T-cell antigen receptor occupancy. Annu. Rev. Immunol., 7:445-480 (1989).
42. Nagata, S. and P. Golstein: The Fas death factor. Science, 267:1449-1456 (1995).
43. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan: The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184:1075-1082 (1996).
44. Pardoux, C., C. Asselin-Paturel, J. Chehimi, F. Gay, F. MamiChouaib, and S. Chouaib: Functional interaction between TGFβ and IL-12 in human primary allogeneic cytotoxicity and proliferative response. J. Immunol., 158:136-143 (1997).
45. Perez, V. L., L. van Parijs, A. Biuckians, X. X. Zeng, T. B. Strom, and A. K. Abbas: Induction of perihperal T-cell tolerance in vivo requires CTLA-4 engagement. Immunity, 6:411-417(1997).
46. Philip, P. A. and L. Flaherty: Treatment of malignant melanoma with interleukin-2. Semin. Oncol., 24:S32-S38 (1997).
47. a-expressing cells. Nature, 339:541-544 (1989).
48. Rocha, B. and H. von Boehmer: Peripheral selection of the T-cell repertoire. Science, 251:1225-1228 (1991).
49. Ruzek, M. C. and A. Mathur: Specific decrease of Th1-like activity in mice with plasma cell tumors. Int. Immunol., 7:1029-1035 (1995).
50. Schwartz, R. H.: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 71:1065-1068 (1992).
51. Scott, B., R. Liblau, S. Degermann, L. A. Marconi, L. Ogata, A. J. Caton, H. O. McDevitt, and D. Lo: A role for non-MHC genetic polymorphism in susceptibility to spontaneous auto-immunity. Immunity, 1:73-83 (1994).
52. Simons, J. W., E. M. Jaffee, C. E. Weber, H. I. Levitsky, W. G. Nelson, M. A. Carducci, A. J. Lazenby, L. K. Cohen, C. C. Finn, S. M. Clift, K. M. Hauda, L. A. Beck, K. M. Leiferman, A. H. Owens, S. Piantadosi, G. Dranoff, R. C. Mulligan, D. M. Pardoll, and F. F. Marshall: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57:1537-1546 (1997).
53. Singh, S., S. R. Ross, M. Acena, D. A. Rowley, and H. Schreiber: Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med., 175:139-146 (1992).
54. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi: Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med., 186:645-653 (1997).
55. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze: Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res., 54:182-189 (1994).
56. Thompson, C. B. and J. P. Allison: The emerging role of CTLA-4 as an immune attenuator. Immunity, 7:445-450 (1997).
57. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton: IL-12 induces T helper 1-directed anti-tumor response. J. Immunol., 158:3359-3365 (1997).
58. Van Elsas, A., H. W. Nijman, C. E. Van der Minne, J. Mourer, W. M. Kast, C. J. Melief, and P. I. Schrier: Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A0201. Int. J. Cancer, 61:389-396 (1995).
59. van't Veer, L. J., B. M. Burgering, R. Versteeg, A. J. Boot, D. J. Ruiter, S. Osanto, P. I. Schrier, and J. L. Bos: N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol., 9:3144-3116 (1989).
60. Wick, M., P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186:229-238 (1997).
61. Zhang, L., D. R. Martin, W. P. Fung-Leung, H. S. Teh, and R. G. Miller: Peripheral deletion of mature CD8+ antigen-specific T cells after in vivo exposure to male antigen. J. Immunol., 148:3740-3745 (1992).
62. Zitvogel, L., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze: IL-12 and B7-1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol., 26:1335-1341 (1996).